TABLE 6.
Adverse events
| Adverse eventa | % (n) |
|
|---|---|---|
| Cirrhotic patients (n = 16) | Healthy volunteers (n = 16) | |
| Supraventricular tachycardia | 6.3 (1) | 0 |
| Atrial fibrillation paroxysm | 6.3 (1) | 0 |
| Premature ventricular contractions | 6.3 (1) | 0 |
| Mild somnolence | 6.3 (1) | 0 |
a
These first adverse events occurred in the same patient on day 4 after a single dose of narlaprevir at 200 mg (part 1), including premature supraventricular contractions, which was considered serious and possibly related to study treatment. It developed in a 67-year-old patient with arterial hypertension and previous episodes of premature ventricular contractions in her medical history. All adverse events in this patient resolved with appropriate medical treatment.